Kiniksa Pharmaceuticals Q1 2026 Earnings EPS Surprises by 315 Despite Stock Decline NNDM Q1 2026 Earnings Loss Per Share of 034 as Stock Rises Amid Strategic Progress VRCA Q1 2026 Earnings EPS Misses Estimates as Commercialization Costs Weigh on Results CPF Q1 2026 Earnings EPS Beats Estimates by 44 Amid Solid Operating Performance PCG Q1 2026 Earnings EPS Beats Estimates by 187 as Utility Navigates Regulatory Landscape AESI Q1 2026 Earnings Earnings Miss Expectations Stock Dips on WiderThanExpected Loss